Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495712 · ClinicalTrials.gov registry record · Phase 4
Antiarrhythmic Effects of Spironolactone in Patients With ICDs
A Phase 4 study of Ventricular Arrhythmias, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04495712: Completed Phase 4 study of Ventricular Arrhythmias, sponsored by VA Office of Research and Development.
NCT04495712 is a Phase 4 study of Ventricular Arrhythmias that has completed, run by VA Office of Research and Development. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04495712, a Phase 4 study of Ventricular Arrhythmias, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether spironolactone, an approved drug for among other things hypertension, will reduce the risk of severe arrhythmias in patients with implanted defibrillators. Half the patients in the study will get spironolactone and half will get a placebo. Neither the patients or their providers will know if they are getting spironolactone or placebo.
Primary Outcome
Time to first documented ICD therapy for ventricular tachycardia or ventricular fibrillation after randomization
Conditions Studied
Interventions
- DRUG placebo
- DRUG spironolactone
Study Locations (1)
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-07-28 |
| Est. Completion | 2008-05-28 |
| Phase | Phase 4 |
What the finished NCT04495712 record still lists
NCT04495712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Ventricular Arrhythmias appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT04495712 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04495712 about?
NCT04495712 is a clinical study titled "Antiarrhythmic Effects of Spironolactone in Patients With ICDs". This study will test whether spironolactone, an approved drug for among other things hypertension, will reduce the risk of severe arrhythmias in patients with implanted defibrillators. Half the patients in the study will get spironolactone and half will get a placebo. Neither the patients or their p...
What is the current status of trial NCT04495712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2004-07-28. Estimated completion is 2008-05-28.
What conditions does trial NCT04495712 study?
This clinical trial studies the following conditions: Ventricular Arrhythmias.
What interventions are being tested in trial NCT04495712?
The interventions under investigation include: placebo (DRUG), spironolactone (DRUG).
Who is sponsoring clinical trial NCT04495712?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04495712 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventricular Arrhythmias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04495712's enrollment target sits among peer trials
90 886th of 2000 higher than 1,089 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI